7wireVentures led a $43m Series B round in Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, with participation from General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, Leaps by Bayer, SV Health Investors, H.I.G. Capital, and Bluestem Capital. "At such an exciting time in the company’s development we are fortunate and excited to welcome our new and existing Series B investors, as well as Glen Tullman as our new Executive Chairman. Zerigo Health continues to gain traction in the market and is well positioned to meet the growing demand by patients to be able to treat their chronic skin conditions wherever they may be. This new investment capital will help fuel our growth in the health plan and self-insured employer markets as they are eager to offer more cost effective and clinically proven solutions for treating these conditions," John E. Schellhorn, Zerigo Health President and CEO.